| +0.50 / +1.03%|
The 29 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 49.55, with a high estimate of 62.44 and a low estimate of 32.43. The median estimate represents a +1.19% increase from the last price of 48.97.
The current consensus among 30 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.